{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:21Z","timestamp":1792788021371,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J01697"],"award-info":[{"award-number":["2022J01697"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian Province Financial Subsidy Health Special Project (","award":["BPB-2024CXW"],"award-info":[{"award-number":["BPB-2024CXW"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06906-4","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:04:05Z","timestamp":1761905045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The integrin \u03b12-osteoclast axis: a key driver of bone destruction and therapeutic target in osteosarcoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Hongxiang","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangfeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"6906_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061182","author":"R Rathore","year":"2021","unstructured":"Rathore R, Van Tine BA. Pathogenesis and current treatment of osteosarcoma: perspectives for future therapies. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10061182.","journal-title":"J Clin Med"},{"issue":"22","key":"6906_CR2","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra2103423","volume":"385","author":"PS Meltzer","year":"2021","unstructured":"Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. N Engl J Med. 2021;385(22):2066\u201376.","journal-title":"N Engl J Med"},{"key":"6906_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010172","author":"A Smrke","year":"2021","unstructured":"Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Future directions in the treatment of osteosarcoma. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10010172.","journal-title":"Cells"},{"key":"6906_CR4","doi-asserted-by":"publisher","first-page":"215887","DOI":"10.1016\/j.canlet.2022.215887","volume":"547","author":"Y Wen","year":"2022","unstructured":"Wen Y, Tang F, Tu C, Hornicek F, Duan Z, Min L. Immune checkpoints in osteosarcoma: recent advances and therapeutic potential. Cancer Lett. 2022;547:215887.","journal-title":"Cancer Lett"},{"key":"6906_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186885","author":"I Lilienthal","year":"2020","unstructured":"Lilienthal I, Herold N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21186885.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"6906_CR6","doi-asserted-by":"publisher","first-page":"e2302746","DOI":"10.1002\/adhm.202302746","volume":"13","author":"K Sun","year":"2024","unstructured":"Sun K, Yuan L, Chen S, Sun Y, Wei D. Alendronate Pt(IV) prodrug amphiphile for enhanced chemotherapy targeting and bone destruction inhibition in osteosarcoma. Adv Healthc Mater. 2024;13(7):e2302746.","journal-title":"Adv Healthc Mater"},{"issue":"43","key":"6906_CR7","doi-asserted-by":"publisher","first-page":"29864","DOI":"10.1021\/acsnano.4c10053","volume":"18","author":"Y Chen","year":"2024","unstructured":"Chen Y, Chen QW, Fu FS, Gu HY, Yu A, Zhang XZ. Bone destruction-chemotactic osteoprogenitor cells deliver liposome nanomedicines for the treatment of osteosarcoma and osteoporosis. ACS Nano. 2024;18(43):29864\u201379.","journal-title":"ACS Nano"},{"key":"6906_CR8","doi-asserted-by":"publisher","first-page":"100996","DOI":"10.1016\/j.mtbio.2024.100996","volume":"25","author":"L Ye","year":"2024","unstructured":"Ye L, Yu C, Xia J, Ni K, Zhang Y, Ying X, Xie D, Jin Y, Sun R, Tang R, et al. Multifunctional nanomaterials via cell cuproptosis and oxidative stress for treating osteosarcoma and OS-induced bone destruction. Mater Today Bio. 2024;25:100996.","journal-title":"Mater Today Bio"},{"issue":"1","key":"6906_CR9","doi-asserted-by":"publisher","first-page":"e2412014","DOI":"10.1002\/advs.202412014","volume":"12","author":"L Li","year":"2025","unstructured":"Li L, Rong G, Gao X, Cheng Y, Sun Z, Cai X, Xiao J. Bone-targeted fluoropeptide nanoparticle inhibits NF-kappaB signaling to treat osteosarcoma and tumor-induced bone destruction. Adv Sci. 2025;12(1):e2412014.","journal-title":"Adv Sci"},{"key":"6906_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110398","author":"B Navet","year":"2018","unstructured":"Navet B, Ando K, Vargas-Franco JW, Brion R, Amiaud J, Mori K, Yagita H, Mueller CG, Verrecchia F, Dumars C, et al. The intrinsic and extrinsic implications of RANKL\/RANK signaling in osteosarcoma: from tumor initiation to lung metastases. Cancers. 2018. https:\/\/doi.org\/10.3390\/cancers10110398.","journal-title":"Cancers"},{"issue":"317","key":"6906_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12967-015-0674-y","volume":"7","author":"Y Chen","year":"2015","unstructured":"Chen Y, Di Grappa MA, Molyneux SD, McKee TD, Waterhouse P, Penninger JM, Khokha R. RANKL blockade prevents and treats aggressive osteosarcomas. Sci Transl Med. 2015;7(317):317\u2013197.","journal-title":"Sci Transl Med"},{"issue":"1","key":"6906_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.gendis.2018.12.003","volume":"6","author":"V Adorno-Cruz","year":"2019","unstructured":"Adorno-Cruz V, Liu H. Regulation and functions of integrin alpha2 in cell adhesion and disease. Genes Dis. 2019;6(1):16\u201324.","journal-title":"Genes Dis"},{"issue":"1","key":"6906_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10555-010-9211-x","volume":"29","author":"R Rathinam","year":"2010","unstructured":"Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 2010;29(1):223\u201337.","journal-title":"Cancer Metastasis Rev"},{"issue":"12","key":"6906_CR14","doi-asserted-by":"publisher","first-page":"e115276","DOI":"10.1371\/journal.pone.0115276","volume":"9","author":"A Ferraro","year":"2014","unstructured":"Ferraro A, Boni T, Pintzas A. EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 gene. PLoS ONE. 2014;9(12):e115276.","journal-title":"PLoS ONE"},{"key":"6906_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12575-018-0073-x","volume":"20","author":"YC Chuang","year":"2018","unstructured":"Chuang YC, Wu HY, Lin YL, Tzou SC, Chuang CH, Jian TY, Chen PR, Chang YC, Lin CH, Huang TH, et al. Blockade of ITGA2 induces apoptosis and inhibits cell migration in gastric cancer. Biol Proced Online. 2018;20:10.","journal-title":"Biol Proced Online"},{"issue":"7","key":"6906_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/pros.22954","volume":"75","author":"SP Chin","year":"2015","unstructured":"Chin SP, Marthick JR, West AC, Short AK, Chuckowree J, Polanowski AM, Thomson RJ, Holloway AF, Dickinson JL. Regulation of the ITGA2 gene by epigenetic mechanisms in prostate cancer. Prostate. 2015;75(7):723\u201334.","journal-title":"Prostate"},{"issue":"8","key":"6906_CR17","doi-asserted-by":"publisher","first-page":"e0135128","DOI":"10.1371\/journal.pone.0135128","volume":"10","author":"W Ding","year":"2015","unstructured":"Ding W, Fan XL, Xu X, Huang JZ, Xu SH, Geng Q, Li R, Chen D, Yan GR. Epigenetic silencing of ITGA2 by MiR-373 promotes cell migration in breast cancer. PLoS ONE. 2015;10(8):e0135128.","journal-title":"PLoS ONE"},{"issue":"8","key":"6906_CR18","doi-asserted-by":"publisher","first-page":"12884","DOI":"10.1002\/jcp.27953","volume":"234","author":"J Gong","year":"2019","unstructured":"Gong J, Lu X, Xu J, Xiong W, Zhang H, Yu X. Coexpression of UCA1 and ITGA2 in pancreatic cancer cells target the expression of miR-107 through focal adhesion pathway. J Cell Physiol. 2019;234(8):12884\u201396.","journal-title":"J Cell Physiol"},{"issue":"9","key":"6906_CR19","first-page":"1564","volume":"7","author":"X Zhao","year":"2015","unstructured":"Zhao X, Wu Y, Lv Z. miR-128 modulates hepatocellular carcinoma by inhibition of ITGA2 and ITGA5 expression. Am J Transl Res. 2015;7(9):1564\u201373.","journal-title":"Am J Transl Res"},{"issue":"1","key":"6906_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s13046-019-1496-1","volume":"38","author":"D Ren","year":"2019","unstructured":"Ren D, Zhao J, Sun Y, Li D, Meng Z, Wang B, Fan P, Liu Z, Jin X, Wu H. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway. J Exp Clin Cancer Res. 2019;38(1):485.","journal-title":"J Exp Clin Cancer Res"},{"key":"6906_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3389\/fonc.2020.00308","volume":"10","author":"Q Wang","year":"2020","unstructured":"Wang Q, Cao T, Guo K, Zhou Y, Liu H, Pan Y, Hou Q, Nie Y, Fan D, Lu Y, et al. Regulation of integrin subunit alpha 2 by miR-135b-5p modulates chemoresistance in gastric cancer. Front Oncol. 2020;10:308.","journal-title":"Front Oncol"},{"issue":"4","key":"6906_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/carcin\/bgad096","volume":"45","author":"J Zhang","year":"2024","unstructured":"Zhang J, Li R, Zhang H, Wang S, Zhao Y. ITGA2 as a prognostic factor of glioma promotes GSCs invasion and EMT by activating STAT3 phosphorylation. Carcinogenesis. 2024;45(4):235\u201346.","journal-title":"Carcinogenesis"},{"key":"6906_CR23","doi-asserted-by":"publisher","first-page":"112487","DOI":"10.1016\/j.intimp.2024.112487","volume":"137","author":"J Qin","year":"2024","unstructured":"Qin J, Hu S, Lou J, Xu M, Gao R, Xiao Q, Chen Y, Ding M, Pan Y, Wang S. Selumetinib overcomes ITGA2-induced 5-fluorouracil resistance in colorectal cancer. Int Immunopharmacol. 2024;137:112487.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"6906_CR24","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1038\/s41598-019-42643-7","volume":"9","author":"P Guo","year":"2019","unstructured":"Guo P, Moses-Gardner A, Huang J, Smith ER, Moses MA. ITGA2 as a potential nanotherapeutic target for glioblastoma. Sci Rep. 2019;9(1):6195.","journal-title":"Sci Rep"},{"issue":"1","key":"6906_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-024-03319-w","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu Y, He M, Tang H, Xie T, Lin Y, Liu S, Liang J, Li F, Luo K, Yang M, et al. Single-cell and spatial transcriptomics reveal metastasis mechanism and microenvironment remodeling of lymph node in osteosarcoma. BMC Med. 2024;22(1):200.","journal-title":"BMC Med"},{"key":"6906_CR26","doi-asserted-by":"publisher","first-page":"618662","DOI":"10.3389\/fonc.2021.618662","volume":"11","author":"T Luo","year":"2021","unstructured":"Luo T, Zhou X, Jiang E, Wang L, Ji Y, Shang Z. Osteosarcoma cell-derived small extracellular vesicles enhance osteoclastogenesis and bone resorption through transferring MicroRNA-19a-3p. Front Oncol. 2021;11:618662.","journal-title":"Front Oncol"},{"key":"6906_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136865","author":"KS Norregaard","year":"2021","unstructured":"Norregaard KS, Jurgensen HJ, Gardsvoll H, Engelholm LH, Behrendt N, Soe K. Osteosarcoma and metastasis associated bone degradation-a tale of osteoclast and malignant cell cooperativity. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22136865.","journal-title":"Int J Mol Sci"},{"key":"6906_CR28","doi-asserted-by":"publisher","first-page":"1506225","DOI":"10.3389\/fimmu.2024.1506225","volume":"15","author":"L Sun","year":"2024","unstructured":"Sun L, Zhang J, Xiahou Z, Zhao Z, Liang Y. Single-cell RNA sequencing revealed PPARG promoted osteosarcoma progression: based on osteoclast proliferation. Front Immunol. 2024;15:1506225.","journal-title":"Front Immunol"},{"issue":"3","key":"6906_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.tranon.2014.04.011","volume":"7","author":"R Garimella","year":"2014","unstructured":"Garimella R, Washington L, Isaacson J, Vallejo J, Spence M, Tawfik O, Rowe P, Brotto M, Perez R. Extracellular membrane vesicles derived from 143B osteosarcoma cells contain pro-osteoclastogenic cargo: a novel communication mechanism in osteosarcoma bone microenvironment. Transl Oncol. 2014;7(3):331\u201340.","journal-title":"Transl Oncol"},{"issue":"10","key":"6906_CR30","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1158\/1078-0432.CCR-15-1925","volume":"22","author":"B Ory","year":"2016","unstructured":"Ory B, Baud\u2019huin M, Verrecchia F, Royer BB, Quillard T, Amiaud J, Battaglia S, Heymann D, Redini F, Lamoureux F. Blocking HSP90 addiction inhibits tumor cell proliferation, metastasis development, and synergistically acts with zoledronic acid to delay osteosarcoma progression. Clin Cancer Res. 2016;22(10):2520\u201333.","journal-title":"Clin Cancer Res"},{"key":"6906_CR31","doi-asserted-by":"publisher","first-page":"1100063","DOI":"10.3389\/fendo.2022.1100063","volume":"13","author":"Z Shao","year":"2022","unstructured":"Shao Z, Bi S. Endocrine regulation and metabolic mechanisms of osteopontin in the development and progression of osteosarcoma, metastasis and prognosis. Front Endocrinol. 2022;13:1100063.","journal-title":"Front Endocrinol"},{"issue":"6","key":"6906_CR32","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/jbmr.2182","volume":"29","author":"T Ohba","year":"2014","unstructured":"Ohba T, Cole HA, Cates JM, Slosky DA, Haro H, Ando T, Schwartz HS, Schoenecker JG. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. J Bone Miner Res. 2014;29(6):1431\u201345.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"6906_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.gendis.2020.01.015","volume":"8","author":"V Adorno-Cruz","year":"2021","unstructured":"Adorno-Cruz V, Hoffmann AD, Liu X, Dashzeveg NK, Taftaf R, Wray B, Keri RA, Liu H. ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis. Genes Dis. 2021;8(4):493\u2013508.","journal-title":"Genes Dis"},{"key":"6906_CR34","doi-asserted-by":"publisher","first-page":"215855","DOI":"10.1016\/j.canlet.2022.215855","volume":"547","author":"C Zhou","year":"2022","unstructured":"Zhou C, Li S, Bin K, Qin G, Pan P, Ren D, Zhao Y, Xia W, Chen J, Liu J, et al. ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. Cancer Lett. 2022;547:215855.","journal-title":"Cancer Lett"},{"issue":"5","key":"6906_CR35","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/0008-5472.CAN-13-1796","volume":"74","author":"A Dutta","year":"2014","unstructured":"Dutta A, Li J, Lu H, Akech J, Pratap J, Wang T, Zerlanko BJ, FitzGerald TJ, Jiang Z, Birbe R, et al. Integrin alphavbeta6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res. 2014;74(5):1598\u2013608.","journal-title":"Cancer Res"},{"issue":"9","key":"6906_CR36","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1080\/15548627.2020.1833515","volume":"17","author":"H Lu","year":"2021","unstructured":"Lu H, Yang HL, Zhou WJ, Lai ZZ, Qiu XM, Fu Q, Zhao JY, Wang J, Li DJ, Li MQ. Rapamycin prevents spontaneous abortion by triggering decidual stromal cell autophagy-mediated NK cell residence. Autophagy. 2021;17(9):2511\u201327.","journal-title":"Autophagy"},{"issue":"9","key":"6906_CR37","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1158\/0008-5472.CAN-09-3251","volume":"70","author":"KC Nannuru","year":"2010","unstructured":"Nannuru KC, Futakuchi M, Varney ML, Vincent TM, Marcusson EG, Singh RK. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res. 2010;70(9):3494\u2013504.","journal-title":"Cancer Res"},{"issue":"10","key":"6906_CR38","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1002\/jbmr.455","volume":"26","author":"J Rousseau","year":"2011","unstructured":"Rousseau J, Escriou V, Lamoureux F, Brion R, Chesneau J, Battaglia S, Amiaud J, Scherman D, Heymann D, Redini F, et al. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res. 2011;26(10):2452\u201362.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"6906_CR39","doi-asserted-by":"publisher","first-page":"e13411","DOI":"10.1111\/cpr.13411","volume":"56","author":"HL Qu","year":"2023","unstructured":"Qu HL, Sun LJ, Li X, et al. Long non-coding RNA AC018926.2 regulates palmitic acid exposure-compromised osteogenic potential of periodontal ligament stem cells via the ITGA2\/FAK\/AKT pathway. Cell Prolif. 2023;56(8):e13411.","journal-title":"Cell Prolif"},{"issue":"1","key":"6906_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41419-025-07689-8","volume":"16","author":"X Qi","year":"2025","unstructured":"Qi X, Zhou J, Wang P, et al. KLF7-regulated ITGA2 as a therapeutic target for inhibiting oral cancer stem cells. Cell Death Dis. 2025;16(1):354.","journal-title":"Cell Death Dis"},{"issue":"2","key":"6906_CR41","doi-asserted-by":"publisher","first-page":"101328","DOI":"10.1016\/j.gendis.2024.101328","volume":"12","author":"H Luo","year":"2024","unstructured":"Luo H, Chang J, Ren Y, et al. Inhibition of ITGA2 suppresses cervical tumorigenesis and metastasis by targeting the AKT\/mTOR signaling pathway. Genes Dis. 2024;12(2):101328.","journal-title":"Genes Dis"},{"key":"6906_CR42","doi-asserted-by":"publisher","first-page":"6661534","DOI":"10.1155\/2021\/6661534","volume":"2021","author":"L Liu","year":"2021","unstructured":"Liu L, Geng H, Mei C, Chen L. Zoledronic acid enhanced the antitumor effect of cisplatin on orthotopic osteosarcoma by ROS-PI3K\/AKT signaling and attenuated osteolysis. Oxid Med Cell Longev. 2021;2021:6661534.","journal-title":"Oxid Med Cell Longev"},{"key":"6906_CR43","doi-asserted-by":"publisher","first-page":"115492","DOI":"10.1016\/j.bone.2020.115492","volume":"138","author":"L Xing","year":"2020","unstructured":"Xing L, Ebetino FH, Boeckman RK Jr, Srinivasan V, Tao J, Sawyer TK, Li J, Yao Z, Boyce BF. Targeting anti-cancer agents to bone using bisphosphonates. Bone. 2020;138:115492.","journal-title":"Bone"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06906-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:04:06Z","timestamp":1761905046000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06906-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6906"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06906-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper has not been published in any other journal, neither is it presented in any meeting. All authors have approved the manuscript and agree with submission to Journal of orthopaedic translation. The authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Public datasets analyzed in this study are available in the GEO (accession: GSE21257, GSE19276, GSE126209, GSE42352) and TARGET-OS repositories. Restrictions apply to clinical data from the 62 patients due to privacy and ethical regulations. Deidentified datasets generated during this study are available from the corresponding author (Wenming Zhang: 1019040069@qq.com) upon reasonable request, subject to approval by the Institutional Review Board of First Affiliated Hospital of Fujian Medical University (IRB# MTCA, ECFAH Of FMU [2015]084-2). Reagent-related data (e.g., E7820 inhibitor protocols) are included in the Methods section.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}}],"article-number":"1204"}}